Business Description
Resverlogix Corp
NAICS : 325410
SIC : 3741
ISIN : CA76128M1086
Total Employee Number:
18Description
Resverlogix Corp clinical-stage biotechnology company. The company is developing apabetalone (RVX-208), a first-in-class, small molecule that is a selective BET (bromodomain and extra-terminal) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. Apabetalone is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. This selective inhibition of apabetalone on BD2 produces a specific set of biological effects with potentially important benefits for patients with chronic disease, including cardiovascular disease (CVD) and associated comorbidities, and COVID-19.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Equity-to-Asset | -11.3 | |||||
Debt-to-Equity | -0.24 | |||||
Debt-to-EBITDA | -22.44 | |||||
Piotroski F-Score | 3/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -44.2 | |||||
3-Year EPS without NRI Growth Rate | 5.7 | |||||
3-Year FCF Growth Rate | 1.5 | |||||
3-Year Book Growth Rate | -12.1 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 44.54 | |||||
9-Day RSI | 45.87 | |||||
14-Day RSI | 46.62 | |||||
3-1 Month Momentum % | -23.88 | |||||
6-1 Month Momentum % | -9.73 | |||||
12-1 Month Momentum % | 155 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 0.03 | |||||
Quick Ratio | 0.02 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -2.7 | |||||
Shareholder Yield % | -33.17 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROA % | -78.46 | |||||
ROIC % | -20.63 | |||||
3-Year ROIIC % | 49.88 | |||||
ROC (Joel Greenblatt) % | -16434.78 | |||||
Years of Profitability over Past 10-Year | 1 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
EV-to-EBIT | -31.44 | |||||
EV-to-EBITDA | -44.58 | |||||
EV-to-FCF | -9.86 | |||||
Earnings Yield (Greenblatt) % | -3.18 | |||||
FCF Yield % | -21.13 |
GF Valueâ„¢
Resverlogix Corp Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Resverlogix Corp Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-13 | In 138 days | ||
| Second quarter earnings results for 2026 | 2026-08-14 | In 47 days | ||
| General meeting for 2026 | 2026-06-25 15:00 | 0.05 (+3.06%) | ||
| First quarter earnings results for 2026 | 2026-05-15 | 0.06 (+11.32%) | ||
| Annual report for 2025 | 2026-04-10 | 0.06 (+5.26%) | ||
| Fourth quarter earnings results for 2025 | 2026-04-10 | 0.06 (+5.26%) | ||
| Third quarter earnings results for 2025 | 2025-11-13 | 0.06 (-9.02%) | ||
| Second quarter earnings results for 2025 | 2025-08-14 | 0.07 (-12.16%) | ||
| General meeting for 2025 | 2025-06-30 13:00 | 0.02 (-18.37%) | ||
| First quarter earnings results for 2025 | 2025-05-14 | 0.02 (-15.79%) |
Show
Entries
Press Release
| Subject | Date | ||
|---|---|---|---|
| Stonegate Capital Partners Initiates Coverage on Resverlogix Corp. (TSX: RVX) | 2019-04-11 |
Articles on Resverlogix Corp
No articles.